Quanterix (NASDAQ:QTRX) is scheduled to be releasing its Q2 2019 earnings data before the market opens on Tuesday, August 6th. Analysts expect Quanterix to post earnings of ($0.43) per share for the quarter.
Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). The business had revenue of $12.34 million for the quarter, compared to analyst estimates of $11.33 million. Quanterix had a negative return on equity of 76.62% and a negative net margin of 79.48%. On average, analysts expect Quanterix to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
QTRX stock opened at $31.05 on Monday. The firm has a market capitalization of $773.15 million, a price-to-earnings ratio of -21.71 and a beta of 1.25. The company has a current ratio of 3.10, a quick ratio of 2.64 and a debt-to-equity ratio of 0.22. Quanterix has a 12-month low of $13.00 and a 12-month high of $36.15. The firm has a fifty day moving average price of $32.26.
Several equities analysts recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and issued a $38.00 target price on shares of Quanterix in a report on Wednesday, July 24th. Zacks Investment Research lowered shares of Quanterix from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Recommended Story: Bear Market
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.